 SAN DIEGO, Feb. 23, 2021 PRNewswire -- Halozyme Therapeutics, Inc. NASDAQ: HALO Halozyme or the Company, a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, subject to market conditions and other factors, 500 million aggregate... 